Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Enrolls First Patient in Clinical Study to Expand Access to PROPEL Treatment to Broader Patient Population
Toggle Summary Intersect ENT Reports Second Quarter 2014 Results
Second Quarter Revenue Increased 118% Year-Over-Year to $8.6 Million
View HTML
Toggle Summary Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis
Toggle Summary Intersect ENT Announces Closing of its Initial Public Offering
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of
View HTML
Toggle Summary Intersect ENT Announces Pricing of Its Initial Public Offering
MENLO PARK, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc., a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the pricing of its initial public offering of 5,000,000 shares of its common
View HTML
Toggle Summary Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors
Toggle Summary Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman
Toggle Summary Intersect ENT Named One of Forbes Magazine’s “America’s Most Promising Companies” of 2014
Toggle Summary Intersect ENT to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Toggle Summary Intersect ENT Named One of the “Fierce 15” Most Promising Private Companies by FierceMedicalDevices